CTOs on the Move

University HealthSystem Consortium

www.uhc.edu

 
UHC, based in Oak Brook, Ill., and representing 0.7 of the academic medical centers in the United States, is an alliance of 84 academic medical centers and 80 associate members.
  • Number of Employees: 1K-5K
  • Annual Revenue: $0-1 Million
  • www.uhc.edu
  • 2001 Spring Rd Ste 700
    Oak Brook, IL USA 60523-1890
  • Phone: 630.954.1700

Executives

Name Title Contact Details

Similar Companies

Stryker Sustainability Solutions

Stryker Sustainability Solutions is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aspen Health Svc

Aspen Health Svc is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Autonomic Technologies

Welcome. Autonomic Technologies, Inc. (ATI) is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company`s initial product, the ATI Neurostimulation System, is approved in Europe for the treatment of cluster headache. The ATI Neurostimulation System was voted #2 among the Cleveland Clinic’s top 10 medical innovations for 2013, and Autonomic Technologies was named one of FierceMedicalDevices’ Fierce 15 most promising privately held medical device and diagnostics companies in the world.

Infinata

Infinata is a Norwood, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elcelyx Therapeutics

lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.